A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions
Status:
Withdrawn
Trial end date:
2010-07-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare bioavailability between formulations of alprazolam in
tablets to determine their bioequivalence in terms of rate and magnitude of absorption.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborator:
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.